Segment Information

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Segment Information

Segment Information

Segment reporting is prepared on the same basis that the Company’s chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes operating decisions and assesses performance. The Company operates in one segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.

Revenues by Product

Product revenues, net consisted of the following:

	2020		2019		2018
	(in thousands)
TRIKAFTA/KAFTRIO	$	3,863,824	$	420,105	$	—
SYMDEKO/SYMKEVI	628,577		1,417,668		768,657
ORKAMBI	907,512		1,331,891		1,262,166
KALYDECO	802,870		991,062		1,007,502
Total product revenues, net	$	6,202,783	$	4,160,726	$	3,038,325

Revenues by Geographic Location

Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:

	2020		2019		2018
	(in thousands)
United States	$	4,829,282	$	3,062,555	$	2,365,079
Outside of the United States
Europe	1,126,460		885,762		543,179
Other	249,941		214,504		139,339
Total revenues outside of the United States	1,376,401		1,100,266		682,518
Total revenues	$	6,205,683	$	4,162,821	$	3,047,597

Significant Customers

Gross product revenues and accounts receivable from each of the Company’s customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total accounts receivable consisted of the following:

	Percent of Total Gross Product Revenues						Percent of Accounts Receivable
	Year Ended December 31,						As of December 31,
	2020		2019		2018		2020		2019
McKesson Corporation	20	%	17	%	14	%	14	%	22	%
Accredo/Curascript	15	%	14	%	14	%	10	%	15	%
Walgreen Co.	14	%	15	%	20	%	10	%	14	%
Lloyds Pharmacy*	<10%		<10%		<10%		19	%	<10%
*A wholly-owned subsidiary of McKesson Corporation in the U.K.

Long-lived Assets by Location

Long-lived assets by location consisted of the following:

	As of December 31,
	2020		2019
	(in thousands)
United States	$	1,207,748	$	768,572
Outside of the United States
United Kingdom	61,462		57,383
Other	14,888		7,327
Total long-lived assets outside of the United States	76,350		64,710
Total long-lived assets	$	1,284,098	$	833,282